Teva Pharmaceutical Industries ADR Repre (TEVA)
$11.47
0.07 (0.61%)
TEVA Stock Quote Delayed 30 Minutes
Previous Close
$17.08
Market Cap
11.68B
PE Ratio
-0.73
EPS
-15.8
Volume (Avg. Vol.)
34,777
Day's Range
11.54 - 11.54
52-Week Range
6.07 - 13.76
Dividend & Yield
0.07 (0.63%)
TEVA Stock Predictions, Articles, and Teva Pharmaceutical Industries ADR Repre News
Teva Stock Was a Good Buy Last Fall, but It Topped out After This Rally
TEVA stock was a great contrarian play last fall. With opioid liabilities hanging like an anvil over the company, shares were priced for disaster. More than doubling from their 2019 lows, I wouldn't say Teva shares are now "priced to perfection". But, the current share price may be pricing in much of the upside. Bottom Line? Consider TEVA stock a hold. With markets facing volatility, a better entry point could spring up down the road.
Potholes Remain for Teva Pharmaceutical Stock
TEVA stock has rallied as its business has stabilized. But even with shares still cheap, investors shouldn't ignore the myriad risks.
Now That Teva Has Stabilized, Teva Stock Looks Undervalued
The forward price-earnings ratio of Teva stock is only 5, and its trailing price/sales ratio is 0.8. With Teva's financial situation in control and given the company's multiple growth drivers, those valuation metrics are quite low.
Opioids Made TEVA Stock Untouchable But Things Seem to be Changing
TEVA stock is about as far from a feel-good investment as you can get. But the underlying generics drug industry is still an important one, making shares a tough contrarian opportunity.
Positive Earnings Look as If They’re Already Priced in to Teva Stock
Teva stock rose 9% after a positive earnings report. But after $3 billion in cost-cutting, investors may be looking for additional revenue.
3 Reasons Why Beaten-Up Teva Stock Could Have a Big 2020
It increasingly appears that Teva stock is in the early stages of going from multi-year loser to multi-year winner.
Teva Pharmaceuticals Earnings: TEVA Stock Takes 10% Jump on Q4 Beat
Teva Pharmaceuticals (TEVA) earnings for the pharmaceutical company's fourth quarter of 2019 have TEVA stock taking off on Wednesday.
Teva Pharmaceutical Just Got a Little Migraine Relief
With plans to capture 25% of the market, the nod from the FDA should help reduce the sting of having to abandon its planned use of Ajovy for cluster headaches, a move that was dropped last year after a failed phase 3 trial, which gave Eli Lilly the market to itself.
There Are Better Pharmaceutical Names Than Teva Stock
Teva Pharmaceuticals may look interesting after its recent surge, but the near-term outlook of TEVA stock is somewhat murky.
Why Teva Stock Could Be the Next General Electric Stock
Teva can handle its debt and deal with its liability from the opioid tragedy. And Teva stock has multiple, positive catalysts.
Why Teva Investors Should Keep Their Hands on the Pause Button
Suffering from many missteps, generics drugmaker Teva is still struggling to heal. Here's what to expect from TEVA stock in 2020.
Buffett Owns Teva Stock, But Should You?
Teva stock has been a long-term loser, but there are signs that things are starting to turn around. Should investors consider it in 2020?
TEVA Stock Isn’t a Cure For Anything That Ails Investors
While Schulz's cost-cutting has reduced Teva's debt by more than $8 billion, more needs to be done to bolster the company's balance sheet.
Scandal-Ridden Teva Pharmaceutical Is Fishing for a Bottom
Teva's debt restructuring gives it breathing room through 2021, assuming its legal woes don't get worse. Buy Teva stock at your own risk.
The Diagnosis for Teva Stock Still Looks Grim
Lately, Teva stock has had a nice rally, but this may prove temporary. The fact is that the company faces much uncertainty with the litigation.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
B
